Form 4: Anika Therapeutics Director William Jellison Reports Restricted Stock Unit Grant

Anika Therapeutics, Inc. Director William R. Jellison reported the acquisition of 14,164 restricted stock units (RSUs) as part of his compensation, vesting by June 2026.

Summary

• William R. Jellison, a Director of Anika Therapeutics, Inc. (ANIK), acquired 14,164 restricted stock units (RSUs) on June 20, 2025.
• These RSUs were granted at a price of $0 per unit, indicating they are part of compensation.
• Each RSU represents the contingent right to receive one share of the Company's common stock.
• The RSUs are scheduled to vest in full on the earlier of the 2026 annual meeting of the Company's stockholders or June 20, 2026.
• Following this transaction, Mr. Jellison directly beneficially owns 20,403 shares of common stock.
• Additionally, Mr. Jellison indirectly beneficially owns 2,700 shares of common stock through the Amended and Restated William R. Jellison Trust dated July 3, 2018, where he is a beneficiary and trustee.

Sentiment

Score: 5

Explanation: The document reports a routine insider transaction (RSU grant) which is neutral in sentiment. It aligns director interests with shareholders but does not indicate significant positive or negative operational or financial news.

Positives

• The grant of 14,164 restricted stock units to a director aligns the director's interests with long-term shareholder value.
• The RSUs vest over approximately one year, providing an incentive for continued performance and commitment.

Negatives

• No specific negative points are identified in this routine insider transaction report.

Risks

• The value of the restricted stock units is contingent on the future performance of Anika Therapeutics' common stock.
• The RSUs are subject to a vesting schedule, meaning the shares are not immediately available to the director.

Future Outlook

The 14,164 restricted stock units granted to Director William R. Jellison are scheduled to vest in full on the earlier of the Company's 2026 annual meeting of stockholders or June 20, 2026, aligning future compensation with company performance.

Industry Context

This Form 4 filing reports a routine equity grant to a director, a common practice in the biotechnology and medical device industry to align executive and director incentives with shareholder interests. Such grants are standard components of compensation packages across publicly traded companies, including competitors in the orthopedic and regenerative medicine sectors.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a director is a standard compensation practice within the U.S. public company landscape, particularly in the life sciences and medical technology sectors.
• Companies like Stryker Corporation (SYK), Zimmer Biomet Holdings (ZBH), and Smith & Nephew plc (SNN) frequently utilize RSU grants as part of their executive and director compensation to foster long-term alignment with shareholder value.
• The $0 acquisition price is typical for compensatory RSU grants, and the vesting schedule, tied to a future annual meeting or a specific date, is also a common mechanism to ensure retention and performance incentives.

Corporate Governance

Related Party Transactions

• William R. Jellison transferred 2,700 shares of common stock to the Amended and Restated William R. Jellison Trust dated July 3, 2018, of which he is a beneficiary and trustee. This represents an indirect beneficial ownership by a related party (the director's trust).

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially fostering long-term value creation.

Next Steps

• The 14,164 restricted stock units will vest on the earlier of the 2026 annual meeting of Anika Therapeutics' stockholders or June 20, 2026.

Key Dates

Keywords

Anika Therapeutics, ANIK, Form 4, SEC filing, insider transaction, restricted stock units, RSUs, director compensation, beneficial ownership, equity grant